Single Cell Spatial Transcriptomics Reveals Immunotherapy-Driven Bone Marrow Niche Remodeling in AML

保存先:
書誌詳細
出版年:bioRxiv (Jan 27, 2025)
第一著者: Gui, Gege
その他の著者: Bingham, Molly Anne, Julius Raimund Herzog, Wong-Rolle, Abigail, Dillon, Laura W, Goswami, Meghali, Martin, Edward, Reeves, Jason, Kim, Sean, Bahrami, Arya, Degenhardt, Hermann, Zaki, George, Prajan Divakar, Schrom, Edward C, Calvo, Katherine, Hourigan, Christopher S, Hansen, Kasper D, Chen, Zhao
出版事項:
Cold Spring Harbor Laboratory Press
主題:
オンライン・アクセス:Citation/Abstract
Full Text - PDF
Full text outside of ProQuest
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
その他の書誌記述
抄録:Given the successful graft-versus-leukemia cell treatment effect observed with allogeneic hematopoietic stem cell transplant for patients with refractory or relapsed acute myeloid leukemia, immunotherapies have also been investigated in the nontransplant setting. Here, we use a multi-omic approach to investigate spatiotemporal interactions in the bone marrow niche between leukemia cells and immune cells in patients with refractory or relapsed acute myeloid leukemia treated with a combination of the immune checkpoint inhibitor pembrolizumab and hypomethylating agent decitabine. We derived precise segmentation data by extensively training nuclear and membrane cell segmentation models, which enabled accurate transcript assignment and deep learning-feature-based image analysis. To overcome read-depth limitations, we integrated the single-cell RNA sequencing data with single-cell-resolution spatial transcriptomic data from the same sample. Quantifying cell-cell distances between cell edges rather than cell centroids allowed us to conduct a more accurate downstream analysis of the tumor microenvironment, revealing that multiple cell types of interest had global enrichment or local enrichment proximal to leukemia cells after pembrolizumab treatment, which could be associated with their clinical responses. Furthermore, ligand-receptor analysis indicated a potential increase in TWEAK signaling between leukemia cells and immune cells after pembrolizumab treatment.Competing Interest StatementJ.D., S.K., A.B., and P.D. are employees and stockholders at NanoString Technologies Inc. All other authors declare no competing interests.Footnotes* https://github.com/chenzhaolab2023/AML-Spatial
ISSN:2692-8205
DOI:10.1101/2025.01.24.634753
ソース:Biological Science Database